ClinicalTrials.gg
RecruitingNCT06158477Updated Nov 18, 2024

A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors

A Phase 1 interventional study of JYP0035 Experimental Drug Treatment in Advanced Solid Tumors, sponsored by Chengdu JOYO pharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Chengdu JOYO pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:

  • What is the safety profile of JYP0035 when administered to these patients?
  • How does JYP0035 capsule behave in the body pharmacokinetically?

Participants will:

  • Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
  • Continue with the identified dose in the dose-expansion phase (PART-2).

As this is a single-arm study, there is no comparison group.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Chengdu JOYO pharma Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients voluntarily participate in the clinical trial and sign the form
  • Age 18 years and above (inclusive), and below 75 years of age (inclusive), with no gender restrictions
  • (Eastern Cooperative Oncology Group)performance status of 0 or 1
  • Expected survival time of ≥3 months
  • During the screening period, female patients of must have a negative serum pregnancy test within 7 days prior to administration of the study drug
  • Participants agree to use reliable methods from signing the informed consent form until 6 months after the last dose of the study drug. This includes, but is not limited to: abstinence, vasectomy in males, female sterilization, effective intrauterine devices, and effective contraceptive medications

Exclusion criteria

Exclusion Criteria:

  • Participants have not recovered to normal or ≤ Grade 1 from any adverse events and/or complications caused by any previous treatments before the first administration of the study drug, excluding hair loss and pigmentation
  • Patients with imaging (CT or MRI) showing tumor invasion into major blood vessels (such as the aorta, pulmonary arteries and veins, vena cava, etc.)
  • Patients who have had cardiovascular or cerebrovascular diseases within 6 months before the first administration, which, in the investigator's judgment, may interfere with the patient's full participation in the study; atrial fibrillation; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
  • Patients who had history of type 1 diabetes, type 2 diabetes, or gestational diabetes
  • Individuals with other or with a history of other malignant tumors
  • Individuals with a history of severe allergies, or who are allergic to any active or inactive ingredients of the study drug
  • Pregnant or breastfeeding patients
  • Researchers consider participants unsuitable for this clinical study due to any clinical or laboratory abnormalities or other reasons
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    JYP0035 monotherapy dose-escalation group

    PART-1 Single Dose Escalation Group

    Drug: JYP0035 Experimental Drug Treatment

  • Experimental
    JYP0035 monotherapy dose-expansion group

    PART-2 JYP0035 Monotherapy Dose Expansion Group

    Drug: JYP0035 Experimental Drug Treatment

Interventions

  • DrugJYP0035 Experimental Drug Treatment

    Single dose intervention

06

What researchers measure

Primary outcomes

  1. Assess the adverse event rate of this clinical trial

    Grading the adverse events using National Cancer Institute - Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 5.0.

    Time frame: From 8 weeks after the first administration up to week 52

Secondary outcomes

  1. Assess Area Under the Curve(AUC)

    Area under the plasma concentration-time curve from zero to infinity

    Time frame: From 8 weeks after the first administration up to week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 6, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06158477
Lead sponsor
Chengdu JOYO pharma Co., Ltd.
Collaborators
Guangzhou JOYO Pharma Co., Ltd
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Jan 1, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 18, 2024

Study contacts

Zhang Jian, MD
Contact
Syner2000@163.com
021-34778299 ext. 086
Huang Hongming, MD
Contact
Honghm3@mail.sysu.edu.cn
028-85420509 ext. 086

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion